Epilepsy

At the 12-month mark, more than 64% of patients had remained on perampanel, with an overall mean retention time of 10.8 months.

Here's what is coming soon to NeurologyLive®.

The clinical psychologist at Cleveland Clinic discussed the potential of using cognitive behavioral therapy for treatment of psychogenic non-epileptic seizures on cognitive behavioral therapy. [WATCH TIME: 3 minutes]

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Findings were presented at AES 2021, with 56.7% of patients reporting a 50% or greater reduction in seizure frequency.

Data suggest that roughly 1 in 100 patients hospitalized with COVID-19 infection will develop central nervous system complications.

Neurology News Network for the week ending December 4, 2021. [WATCH TIME: 4 minutes]

Two experts explain the impact of the drug fenfluramine’s FDA approval in the treatment of Dravet syndrome.

Drs Thiele and Wirrell continue analyzing the benefits of cannabidiol as a therapeutic option for patients with Dravet or Lennox-Gastaut syndromes.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 3, 2021.

More than two-thirds of patients who received prednisolone after showing no response to vigabatrin demonstrated complete electroclinical response at 2 weeks, with most sustaining response at 6 weeks.

There was a statistically significant difference in epileptic seizure frequency means across baseline and the 6- and 12-month follow-up visits.

Expert clinicians offer their perspectives on transitional care in pediatric MS, a biomarker for SUDEP, and a novel approach to narcolepsy, among other topics.

After demonstrating a significant effect in reducing the frequency of drop seizures, fenfluramine aims to build on its previous indication in rare epileptic disorders, as it is currently approved to treat Dravet syndrome.

In addition to a well-tolerated safety profile, investigators observed a dose proportional increase in plasma pharmacodynamics in the MONARCH study cohort of 21 children and adolescents.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending November 27, 2021.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 26, 2021.

In a NeurologyLive® Insights series, experts in the diagnosis and treatment of Dravet syndrome discussed the management of the disease and the utilization of approved treatments to improve outcomes in patients.

The director of the Comprehensive Epilepsy Center at NYU Langone provided closing thoughts on how clinicians can begin to shift gears from research to prevention of SUDEP. [WATCH TIME: 2 minutes]

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the large-scale impact heart rate variability has on preventing SUDEP and the unanswered questions that remain.

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the necessary steps in validating and utilizing heart rate variability as a biomarker for SUDEP. [WATCH TIME: 3 minutes]

Reduced low-frequency power measured at rest was independently associated with an elevated SUDEP risk, presumably through arrhythmogenic mechanisms.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending November 20, 2021.